CD47 and diffuse large B-cell lymphoma: Among the most promising combinations, the synergistic FcR-dependent activation of phagocytosis by the anti-CD47 mAb Hu5F9-G4 associated to rituximab signaling has demonstrated great effectivity in B-NHL cell lines and primary samples (31), and has further shown promising clinical activity with few side effect in the phase Ib clinical trial NCT02953509 involving R/R DLBCL and FL patients (32).